LuAG-06474 is under clinical development by H. Lundbeck and currently in Phase I for Unspecified Neurologic Disorders.

KNX-100 is under clinical development by Kinoxis Therapeutics and currently in Phase II for Unspecified Psychiatric Disorders.

Brad Rowell pleaded guilty to ten counts involving two victims, including lewd acts upon a child, unlawful sexual intercourse ...

The new Frontwave Arena in Oceanside is the site of this year’s Holo Holo Music Festival, a celebration of island and reggae ...

The Labour Party government has promised to honour the Conservative Party pledge to cut £3bn from the welfare bill.

Autolus Therapeutics plc (Nasdaq: AUTL), a commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed T cell therapies, announces an oral ...

The seek unspecified damages ... and Winslow was diagnosed with post-traumatic stress disorder, depression, and anxiety, “all largely connected to the retaliation and harassment against him ...

Ongoing commercial launch of AUCATZYL® on track, with 24 treatment centers fully authorized as of January 10th- National Comprehensive Cancer ...

Our recovery programs work with many challenging issues - severe depression, anxiety ... binge eating and other unspecified eating disorders through an unmatched network of 24 centers in 7 ...

Anxiety Institute provides a specialized ... binge eating, ARFID and other unspecified eating disorders through an unmatched network. Eating Recovery Center of Maryland offers Partial ...